Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer's disease (AD). Whether the individual-specific response, specific ChEI agent or dose affects mortality is unclear. We aimed to examine the relationship between the 6-month response to ChEI and lifespan. METHODS: Six hundred and eighty-one deceased patients with a clinical AD diagnosis and a Mini-Mental State Examination (MMSE) score of 10-26 at the start of ChEI therapy (baseline) were included in a prospective, observational, multicentre study in clinical practice. At baseline and after 6 months of treatment, the participants were assessed using the MMSE, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), the Clinician's Interview-Based Impression of Change (CIBIC), the Instrumental Activities of Daily Living (IADL) scale, and the Physical Self-Maintenance Scale (PSMS). The individuals' socio-demographic characteristics, ChEI dose, and date of death were recorded. Responses to ChEI and the association of possible risk factors with survival were analysed using general linear models. RESULTS: A longer lifespan (mean of 0.5 years) was observed among the improved/unchanged patients, as measured by MMSE or CIBIC score, but not by ADAS-cog score, after 6 months of ChEI therapy. In the multivariate models, increased survival time was independently related to a better 6-month response in MMSE, CIBIC, IADL, and PSMS scores, female sex, no antihypertensive/cardiac or antidiabetic therapy, younger age, lower education, milder disease stage at baseline, and higher ChEI dose. Apolipoprotein E genotype did not affect mortality significantly. The patients who received a higher ChEI dose during the first 6 months had a mean lifespan after baseline that was 15 months longer than that of those who received a lower dose. CONCLUSIONS: A better short-term response to ChEI might prolong survival in naturalistic AD patients. In individuals who received and tolerated higher ChEI doses, a longer lifespan can be expected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“A modest post-treatment improvement in cognitive rating scales for about 6–12 months before the score returned to baseline value was reported by previous AD studies [32-34].”
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Fried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107 · cited 2×
“Consistently, co-morbid disorders, particularly cardio/cerebrovascular and respiratory diseases, and diabetes, increase mortality in most dementia studies [14,17,39] and in the general population [40].”
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Stern, Y., Tang, M. X., Denaro, J., & Mayeux, R. (1995) · Annals of Neurology · doi:10.1002/ana.410370508 · Cited by 252
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · cited 4×
“The Statistical Package for Social Sciences (SPSS) software (version 21.0; IBM Corporation, Armonk, NY, USA) was used to perform the statistical analyses.”
InfluentialWallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · cited 1×
“SATS is a 3-year, open-label, observational, nonrandomised, multicentre study that has been described in earlier publications [12,20,21].”
Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181f5dd97 · Cited by 52 · cited 2×
“SATS is a 3-year, open-label, observational, nonrandomised, multicentre study that has been described in earlier publications [12,20,21].”
Self-citation
Cited by
Considering sex and gender in Alzheimer disease and other dementias
Podcasy, J. L., & Epperson, C. N. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/cepperson · Cited by 707
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011832 · Cited by 182
Li, K., Wang, J., Li, S., Yu, H., Zhu, L., Liu, J., & Wu, L. (2021) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2021.3101240 · Cited by 61
Yaghmaei, E., Lu, H., Ehwerhemuepha, L., Zheng, J., Danioko, S., Rezaie, A., Sajjadi, S. A., & Rakovski, C. (2024) · Communications Medicine · doi:10.1038/s43856-024-00527-6 · Cited by 47
Metadata
- Authors
- Wattmo, C., Londos, E., & Minthon, L.
- Venue
- BMC Neurology
- Published
- 2014-09-10
- Volume
- 14
- Issue
- 1
- Pages
- 173-173
- ISSN
- 1471-2377 (ISSN-L)
- OpenAlex
- W2035721215
- Cited by
- 30
- References
- 9
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s12883-014-0173-4
- The paper
- Wattmo, C., Londos, E., & Minthon, L. (2014). Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease. BMC Neurology. https://doi.org/10.1186/s12883-014-0173-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.